Clinical trial NCT01635127: Efficacy Study of Canakinumab to Treat Urticaria
Official title: A Phase II Randomized Double-Blind Placebo Controlled Single Center Study of Canakinumab Treatment of Adult Patients With Moderate to Severe Chronic Idiopathic Urticaria
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Chronic Idiopathic Urticaria
Lead sponsor: University of Zurich
Sponsor class: OTHER
First posted: 2012-07-06
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: Evaluation whether canakinumab leads to improvement of urticaria

Detailed description: Single center prospective placebo-controlled cross-over phase II study.

* To assess if canakinumab can induce clinical improvement and/or complete clinical remission of chronic idiopathic urticaria at week 4 as compared to placebo
* To compare canakinumab and placebo treated patients in the percentage who achieve complete clinical remission at week 1, 2, 4, and 8.
* To compare the percentage with clinical improvement as measured by UAS7 score at week 1, 2, 4, and 8 in canakinumab and placebo treated patients
* To compare the percentage of canakinumab and placebo treated patients with 75% and 100% improvement of their baseline (Run-in-period) UAS7 score at week 1,2,4,and 8
* To compare the daily wheal score for Days 1 to 7 in canakinumab and placebo treated patients

Eligibility criteria: Inclusion criteria

* Diagnosis of chronic idiopathic urticaria for more than 6 weeks as confirmed by clinical and, if necessary, histological examination
* CIU of moderate to severe severity defined by all of the following

  * Physician severity score of 2 or 3 (on a scale from 0 - 3)
  * Run-in period of the diary-based UAS7 score of \> 21 (on a scale from 0 - 42)
  * Symptomatic despite use of non-sedating antihistamine with or without concomitant leukotriene antagonist/corticosteroids
* Use of maintenance non-sedating antihistamine at a stable dose for at least 1 week prior to entering run-in period
* Maintenance corticosteroids at a dose of \<20 mg/day or \<0.4 mg/kg stable for at least the week prior to study entry for treatment of the patient's CIU will be allowed.
* Age: \> 18 years.
* Signed informed consent
* Negative or unreactive QuantiFERON test (QFT-TB G In-Tube) or history of adequate treatment of active or latent tuberculosis.

Exclusion criteria:

* Age \< 18 or \> 70 years
* History of cancer except for treated basal cell carcinoma of the skin
* With active or recurrent bacterial, fungal or viral infection at the time of enrollment, including patients with evidence of Human Immunodeficiency Virus (HIV) infection, Hepatitis B and Hepatitis C infection, active or untreated latent tuberculosis.
* Patients currently treated with systemic immunosuppressive agents or following treatments in the specified period before the baseline visit:

  * corticosteroids =20 mg/day or \>0.4 mg/kg for 1 week prior to study entry;
  * leukotriene antagonists for 1 week prior to study entry
  * colchicine, dapsone or mycophenolate mofetil for 3 weeks;
  * etanercept, leflunomide (documentation of a completion of a full cholestyramine elimination treatment after most recent leflunomide use will be required), thalidomide or ciclosporin for 4 weeks;
  * adalimumab or intravenous immunoglobulin for 8 weeks;
  * infliximab, 6-mercaptopurine, azathioprine, cyclophosphamide or chlorambucil for 12 weeks
* Live vaccinations within 3 months prior to the start of the trial, during the trial, and up to 3 months following the last dose
* Contraindications to the class of drugs under study, e.g. known hypersensitivity or allergy to class of drugs or the investigational product,
* Pregnant or lactating women, patients (men or women) planning a pregnancy during the duration of the study, lack of safe contraception.
* Safe contraception is defined as follows:
* Double-barrier contraception such as oral, injectable, or implantable contraceptives, or intrauterine contraceptive devices together with condom use.
* Both men and women must use safe contraception (double-barrier as defined above) during the duration of the study and until 6 months after the study.
* Please note that female subjects who are surgically sterilized/hysterectomized or post-menopausal for longer than 2 years are not considered as being of child bearing potential.
* Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the subject.
* Participation in another study with investigational drug within the 30 days preceding and during the present study.
* Previous enrolment into the current study.
* Enrolment of the investigator, his/her family members, employees and other dependent persons.

Primary outcomes:
measure: Complete clinical remission
timeFrame: 4 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Zurich
country: Switzerland
facility: University Hospital Zurich, Division of Dermatology
Study officials:
affiliation: University Hospital Zurich, Division of Dermatology
name: Peter Schmid-Grendelmeier, Prof MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Maul JT, Distler M, Kolios A, Maul LV, Guillet C, Graf N, Imhof L, Lang C, Navarini AA, Schmid-Grendelmeier P. Canakinumab Lacks Efficacy in Treating Adult Patients with Moderate to Severe Chronic Spontaneous Urticaria in a Phase II Randomized Double-Blind Placebo-Controlled Single-Center Study. J Allergy Clin Immunol Pract. 2021 Jan;9(1):463-468.e3. doi: 10.1016/j.jaip.2020.07.058. Epub 2020 Aug 20.